Aurobindo Pharma increases stake in China JV to 50%
Aurobindo Pharma's Dutch arm buys 20% more in China's Luoxin Aurovitas for $5M, aiming for 100% ownership by 2029 to scale up inhalation product manufacturing. Read the full strategic move.
Category : Search result: pharma fundraising
Rs 1.3 Lakh Crore Raised in FY26 via 83 IPOs: NSE
NSE report shows robust fundraising of Rs 1.3 lakh crore in FY26 till November. Retail participation hits 25%. Discover key trends shaping India's capital markets.
India Pharma Targets $500B, Innovation Hub by 2047
India's pharmaceutical industry gears up for a critical 5-year phase from 2026, aiming to become a $500 billion innovation hub by 2047. Learn how it plans to tackle challenges and seize opportunities.
Indian firms raise Rs 1.3 lakh crore in FY25 till November
Indian companies raised a robust Rs 1.3 lakh crore from domestic equity markets in FY25's first eight months, led by IPOs and SME listings. Discover the key drivers and sectors.
Munawar Faruqui exposes alleged charity scam, hints at Elvish Yadav
Bigg Boss 17 winner Munawar Faruqui reveals a shady NGO offer in Amsterdam, warning against fraudulent fundraising. Elvish Yadav responds to indirect allegations. Read the full story.
Elvish Yadav responds to fundraising controversy
Bigg Boss OTT 2 winner Elvish Yadav breaks silence on NGO scam allegations linked to SMA child's fundraiser. He denies taking money, calls drive transparent.
Bangladesh Beats India to Export Weight-Loss Drugs to Emerging Markets
Bangladesh's pharma firms have a 2-year head start over Indian giants like Dr Reddy's in exporting generic semaglutide. Delhi HC allows exports, but domestic sales wait until 2026. Explore the competitive landscape.
Sebi eases HVDLE norms, raises threshold to ₹5,000 crore
Sebi raises HVDLE threshold to ₹5,000 crore, easing compliance for NBFCs, HFCs & others. Move aims to boost corporate bond market & ease of doing business. Details inside.
Corona Remedies IPO Opens: Key Details & Strong GMP
Corona Remedies IPO subscription starts Dec 8. Price band ₹1008-1062, aims to raise ₹655 cr. Grey market premium signals strong investor interest. Details inside.
Corona Remedies IPO Subscription Begins, GMP at ₹290
Corona Remedies' ₹655 crore IPO opens today. With a price band of ₹1,008-₹1,062 and a strong GMP, analysts give a 'Subscribe for long term' rating. Key dates and details inside.
Bengaluru Concert Supports Kids with Blood Cancer
A special concert in Bengaluru today, March 16, aims to raise funds for children battling blood cancer at the Kidwai Memorial Institute of Oncology. Featuring renowned artists, the event supports vital treatment costs.
Odisha Approves Pharma & Medtech Policy 2025
Odisha's new Pharma & Medtech Policy 2025 aims to make the state a strategic hub for healthcare manufacturing. The policy includes plans for dedicated industrial parks and a roadmap aligned with India's 2047 vision. Read more.
Himachal Pharma Sector Faces Major Trust Crisis
Himachal Pradesh's pharmaceutical hub is in turmoil as 38 firms lose WHO-GMP certification, raising serious quality concerns. Discover the causes and impact.
Nivin Pauly's 'Pharma' Trailer Targets Unethical Drug Practices
Nivin Pauly's OTT debut 'Pharma' trailer reveals a medical rep exposing dangerous drugs. The series premieres on JioCinema December 19 in 7 languages. Read more.
Laurus Labs aims for 50% revenue from CDMO business in 5 years
Hyderabad's Laurus Labs plans aggressive CDMO growth, targeting 50% of revenue in five years. CEO Dr. Satyanarayana Chava reveals strategy focusing on cell & gene therapy and global expansion. Read more.
Granules India's US facility passes FDA GMP inspection
Granules India's US subsidiary, Granules Consumer Health LLC, successfully cleared a USFDA GMP inspection with zero observations. This marks a significant achievement for the Hyderabad-based pharma major's OTC product operations in America.
Corona Remedies IPO: Key Dates, Price Band, Details
Corona Remedies IPO opens Dec 8, 2025, to raise ₹655.37 crore. Check price band, GMP, financials, and key dates for this pharma company's public issue.
Retail Investors Lead Record IPO Rally in 2025
India's primary markets see record fundraising of ₹1.61 trillion in 2025, fueled by a sharp 24% retail investor share. Discover the structural shift in household savings and the outlook for 2026.
India's IPO Market Hits Record ₹1.6 Trillion in 2025
India's primary market sees a blockbuster year with 93 IPOs raising over ₹1.6 trillion, set to surpass last year's record. Experts analyze the surge and future outlook. Read more.
Market Opens Strong: Nifty Above 25,400, Gift Nifty Up
Indian stock markets opened strong on December 3, 2025, with Nifty crossing 25,400. Key stocks like TCS and Sun Pharma in focus. Read for full analysis and trading cues.
Corporate funding rebounds 58% in Sep quarter to ₹7.5 tn
Corporate fundraising in India jumped 58.1% year-on-year in the September 2025 quarter to ₹7.5 trillion, driven by soaring profits and renewed bank credit. Explore the key drivers behind this sharp recovery.
India's IPO Boom Continues with Rs 30,000 Cr December Rush
India's primary market gears up for a blockbuster December with 25 IPOs, led by giants like ICICI Pru AMC & Meesho, aiming to raise nearly Rs 30,000 crore. Discover the drivers behind this landmark year.
Wockhardt Shares Jump 6% on USFDA NDA Acceptance for Zaynich
Wockhardt's share price surged over 6% after the USFDA accepted its New Drug Application for Zaynich, a novel antibiotic. Discover the details and market impact.
Sun Pharma's Ilumya for Psoriasis Launched in India
Sun Pharma introduces its global biologic Ilumya for moderate-to-severe plaque psoriasis in India. Backed by Phase-3 data, it offers long-lasting clearance with a strong safety profile. Learn more about this targeted therapy.
Adani's ₹24,930 Crore Boost for Rights Issues
Adani Enterprises' massive rights issue could push 2025-26 collections to ₹39,439 crore, matching previous highs. Explore how this signals a broad-based market revival.
India's Bulk Drug Makers Ramp Up CDMO Investments
Indian API manufacturers are shifting to high-value contract development, targeting $22-25 billion market by 2035 as global pharma diversifies from China. Read about the growth trajectory.
Pharma Chemical Firms Outperform with 7% Growth
Speciality chemical makers supplying pharma CDMOs post 7% sales growth, outpacing non-pharma peers. Strong margins and global shifts fuel this resilient sector. Read more.
VDHM 2024: Rs 4.1 Crore Raised for Charity
The 20th Vedanta Delhi Half Marathon united 40,500 runners and raised Rs 4.1 crore for 16 social causes. Discover how corporates and individuals championed change through philanthropy.
SAR Televenture Reschedules Fundraising Board Meeting
SAR Televenture postpones its crucial board meeting for fundraising to December 5, 2025. The company also reports stellar Q2 results with profit soaring 127% YoY. Details inside.
November 2025 IPO Analysis: Market Trends Revealed
November 2025 witnessed 9 IPOs with 12 listings. Groww leads with 58.85% gains while experts warn of investor fatigue and unrealistic valuations. Read full analysis.
Page 1 of 4